Friday, January 20, 2006

Bird Flu Picks - Update

AVII....Bought 2.25....Current 8.65.......+284%
BCRX....Bought 8.69....Current 20.04......+130%
CRXL....Bought 24.13...Current 25.00......+3%
DVAX....Bought 6.00....Current 5.60.......-6%
HEB.....Bought 2.02....Current 2.66.......+32%
NNVC....Bought 0.09....Current 2.10.......+2233%
NVAX....Bought 1.49....Current 4.95.......+232%
SVA.....Bought 4.05....Current 4.53.......+12%
VICL....Bought 6.00....Current 4.67.......-22%

Average Gain per Pick = +322%

6 comments:

Anonymous said...

just curious, why did you ditch practising Law?

Allan said...

just curious, why did you ditch practising Law?

Nasty business

"Do what you love, or love what you do."

A

john said...

well put. do you know what neil6 thinks about bwng ? do you think bwng and avii are good breakout candidates ? i think i may pick up 1000 shares of each on monday or would you wait ? thanks allan, john

Allan said...

john,

do you know what neil6 thinks about bwng ? do you think bwng and avii are good breakout candidates ?

Don't follow either BWNG or neil6's opinions, can't help you there. As for AVII, Barron's today has a write-up:

AVI is a speculative play. It has no drugs on the market and modest annual revenue of about $25 million. Momentum investors have been attracted to the stock, heightening the risks. Yet if its products work, AVI could soar further. Its market value now is about $400 million. Antisense drugs have been out of favor on the Street, owing to some high-profile failures at rival companies, but AVI believes its next-generation drugs are effective.

"AVI's preclinical results have been good, but investors normally don't give much value to preclinical results," says Reni Benjamin, an analyst at Rodman and Renshaw, a New York brokerage firm. Benjamin, whose rating for the company has been under review since November, says AVI is executing better, but notes that the critical news will be on the hepatitis C trial. AVI has said that if that drug proves successful in the phase I/II trial, it probably will seek the partnership of a big drug company. That would bolster its coffers, its image and its shares.


A

Anonymous said...

"It has no drugs on the market and modest annual revenue of about $25 million."

Yahoo finance says it has $3.5M in annual revenue!

curt504 said...

NNVC, I sold all at 2.57 looking for a swing trade. I'm amazed at the resistance at $2. I missed the tree shake down to $1.65 for about an hour a week ago.

Any thoughts about a likely trickle down over the next week or two? Or news events?

NNVC is tough to guess how it will run and the RB board has almost no DD or tips. LOL

best of luck to you, curt